GANX

Gain Therapeutics (GANX)

About Gain Therapeutics (GANX)

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Details

Daily high
$2.03
Daily low
$1.94
Price at open
$1.99
52 Week High
$5.33
52 Week Low
$0.89
Market cap
50.3M
Dividend yield
0.00%
Volume
81,344
Avg. volume
326,331
P/E ratio
-1.50

Gain Therapeutics News

Details

Daily high
$2.03
Daily low
$1.94
Price at open
$1.99
52 Week High
$5.33
52 Week Low
$0.89
Market cap
50.3M
Dividend yield
0.00%
Volume
81,344
Avg. volume
326,331
P/E ratio
-1.50